PIM
HRTX icon

Partner Investment Management’s Heron Therapeutics HRTX Stock Holding History

Partner Investment Management’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-22,500
Closed -$874K – 123
2018
Q2 		$874K Buy
+22,500
New +$716K 0.71% 52

Other funds holding HRTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

Partner Investment Management's HRTX Position: Q3 2017 in Review

Partner Investment Management sold out of Heron Therapeutics (HRTX) in Q3 2017, closing a stake of 49,038 shares — an estimated $679K sold.

Partner Investment Management first reported a position in HRTX in Q2 2015 and held it in 9 quarters. The position peaked at $1.27M in Q3 2015. 104 funds tracked by Wall St. Rank hold HRTX as of Q3 2017.

  • Partner Investment Management reported no remaining Heron Therapeutics position as of Q3 2017 after selling out during the quarter.
  • Partner Investment Management sold 49,038 Heron Therapeutics shares in Q3 2017, an estimated $679K.
  • Partner Investment Management first reported a position in Heron Therapeutics in Q2 2015 and held it in 9 quarters.
  • Partner Investment Management's Heron Therapeutics position peaked at $1.27M in Q3 2015.
  • 104 funds tracked by Wall St. Rank held Heron Therapeutics as of Q3 2017.

Based on Partner Investment Management's 13F filing for Q3 2017, filed 14 Nov 2017.